GlandokortГландокорт
A peptide mixture extracted from calf or pig adrenal glands, studied in an institute report on stress-related hormones.
What the studies found
Comparison in people · 2011
Glandokort: clinical report on a tissue-derived preparation
- Plasma aldosterone in the adrenal-insufficiency table
- 38.5 ± 1.3 pg/mL with Glandokort versus 26.2 ± 1.6 pg/mL with conventional care. Shared baseline 14.7 ± 1.2 pg/mL.
- Cortisol in the prolonged-stress table
- 431.4 ± 25.7 versus 311.4 ± 21.4 nmol/L. Shared baseline 287.5 ± 18.5 nmol/L.
- ACTH in the prolonged-stress table
- 28.6 ± 1.1 versus 17.4 ± 1.3 pg/mL. The table gives no significance mark for ACTH.
In the adrenal-insufficiency table, plasma aldosterone was 38.5 versus 26.2 pg/mL after adjunctive Glandokort and conventional care, respectively. The subgroup sizes are unclear.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model 36 patients described; 26 controls separately stated. Enrollment denominator unresolved.
Design The report mentions 36 patients and separately describes 26 controls. Assignment and subgroup sizes are unclear. The adjunctive schedule was one 10 mg capsule orally with meals twice daily (20 mg/day) for 30 days. The report excluded patients receiving hormone therapy.
Important limitations
- Resolve enrollment and diagnostic criteria before pooling participants. Hormone-marker changes cannot establish a treatment for nonspecific fatigue. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
- The tables mark aldosterone and cortisol as significant against conventional care. Subgroup sizes and the relationship of the 26 controls to the 36 described patients are unclear.
Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date · Institute report — commercial reproduction
About Glandokort
Identity / background source ↗
Research background
Glandokort is an adrenal tissue peptide preparation. A Medical Center report measured hormone levels during short-term treatment.
- Compound class
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
36 patients described; 26 controls separately stated. Enrollment denominator unresolved.
Study methods
Small comparative institute report; allocation, blinding and outcome interpretation require caution
Independent replication
Independent replication not established in this collection
Source access
Report reproduction linked; source language and review scope shown per record
Safety evidence
Short-term reports do not establish long-term safety or equivalence to current products
Open a topic for the evidence assessment.
Findings by study
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Comparison in people · 2011
Glandokort: clinical report on a tissue-derived preparation
In the adrenal-insufficiency table, plasma aldosterone was 38.5 versus 26.2 pg/mL after adjunctive Glandokort and conventional care, respectively. The subgroup sizes are unclear.
Plasma aldosterone in the adrenal-insufficiency table · 38.5 ± 1.3 pg/mL with Glandokort versus 26.2 ± 1.6 pg/mL with conventional care. Shared baseline 14.7 ± 1.2 pg/mL.
Study notes and original source
Glandokort: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
In the adrenal-insufficiency table, plasma aldosterone was 38.5 versus 26.2 pg/mL after adjunctive Glandokort and conventional care, respectively. The subgroup sizes are unclear.
Results and tables
Reported findings and study design
The report mentions 36 patients and separately describes 26 controls. Assignment and subgroup sizes are unclear. The adjunctive schedule was one 10 mg capsule orally with meals twice daily (20 mg/day) for 30 days. The report excluded patients receiving hormone therapy.
Population or model 36 patients described; 26 controls separately stated. Enrollment denominator unresolved.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Plasma aldosterone in the adrenal-insufficiency table | 38.5 ± 1.3 pg/mL with Glandokort versus 26.2 ± 1.6 pg/mL with conventional care. Shared baseline 14.7 ± 1.2 pg/mL. | |
| Cortisol in the prolonged-stress table | 431.4 ± 25.7 versus 311.4 ± 21.4 nmol/L. Shared baseline 287.5 ± 18.5 nmol/L. | |
| ACTH in the prolonged-stress table | 28.6 ± 1.1 versus 17.4 ± 1.3 pg/mL. The table gives no significance mark for ACTH. |
The tables mark aldosterone and cortisol as significant against conventional care. Subgroup sizes and the relationship of the 26 controls to the 36 described patients are unclear.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 36 patients described; 26 controls separately stated. Enrollment denominator unresolved.
- Source reviewed
- Russian Medical Center report, PDF pages 32–33, methods and hormone tables.
Study limitations
- Resolve enrollment and diagnostic criteria before pooling participants. Hormone-marker changes cannot establish a treatment for nonspecific fatigue.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-16.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗